Close
Digital Health & Ai Innovation summit 2026
APE 2026

NICE announces launch of a new database to inform the prioritisation of European cancer research

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

FDA Gives Clearance to Hugo RAS...

Medtronic, which is a global leader when it comes...

FDA May Scrutinize Medical Device Cybersecurity...

The scrutiny by the US Food and Drug Administration...

Recon DL Tool from GE HealthCare...

Pristina Recon DL tool from GE HealthCare which uses...

The National Institute for Health and Clinical Excellence has launched a new database that will help with the identification and prioritisation of future cancer research across Europe.

The Database of Cancer Uncertainties has been developed through the Coordination of Cancer Clinical Practice Guidelines in Europe initiative. CoCanCPG is a consortium of 16 institutional partners from 11 countries and is funded by the European Commission.

Uncertainties around the evidence base used in guideline development are common, indeed, it is rare that all aspects of the management of a condition are supported by high-quality research evidence. In some circumstances, the research has not been done and even where it has been done it may be methodologically flawed or inconclusive.

The cancer uncertainties database will provide a tool to bring these uncertainties together and link into other initiatives such as the UK’s Database of Uncertainties about the Effects of Treatments – DUETs. The uncertainties will be prioritised with input from clinicians, patients, funders and researchers. The prioritised uncertainties can then be promoted to research funders and researchers across the EU. Tracking mechanisms will be developed to avoid duplication of effort and highlight relevant clinical trials that patients can participate in. The co-ordination will help to ensure that the available research funds are spent against identified priorities.

Latest stories

Related stories

FDA Gives Clearance to Hugo RAS System, Confirms Medtronic

Medtronic, which is a global leader when it comes...

FDA May Scrutinize Medical Device Cybersecurity More in 2026

The scrutiny by the US Food and Drug Administration...

Recon DL Tool from GE HealthCare Receives a PMA

Pristina Recon DL tool from GE HealthCare which uses...

Abbott to Acquire Cancer Test Maker for Around $21 Billion

In a recent move, Abbott has gone ahead and...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »